EUCTR2007-005477-54-IT进行中（未招募）不适用
Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies
OSPEDALE S. RAFFAELE DI MILANO0 个研究点开始时间: 2008年1月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Patients with haematological malignancies such as - acute myeloid leukaemia -AML- in CR1 except 'low-risk cases' defined by: t(15;17); t(8;21); inv 16; normal cytogenetics at diagnosis with FLT3-ITD negative and NPM-1 positive, with any high-risk clinical criteria- any AML beyond CR1- acute lymphoblast leukaemia -ALL- in CR1 only if at 'high risk' defined by cytogenetics as t(9;22), t(4;11), or for persistence of minimal residual disease (MRD)- any ALL beyond CR1- chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP) intolerant/not responsive to TK-inhibitors- myeloproliferative disorders -MPD-- myelodysplastic syndrome -MDS- with intermediate or high risk International Prognostic Scoring System (IPSS)- diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1- lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1- mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1- follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2- Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1- chronic lymphocytic leukaemia -CLL- at 'poor risk' in CR1 or with a chemosensitive relapse- CLL relapsing after high dose chemotherapy- T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond - multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1 following high dose chemotherapy- MM at any relapse/progression, except refractory disease· Lacking of a HLA-identical related (MRD) or unrelated (MUD) donor, eligible to donate· Availability of a mismatched related donor (MMRD) sharing at least one full haplotype or a MUD satisfying the minimum criterion of a 5/6 antigen match at HLA-A, -B and -DRB1 · Target graft size (unmanipulated)- peripheral blood: 4 - 10 x 106 CD34+ cells/kg BW recipient - bone marrow: 2 - 10 x 106 CD34+ cells/kg BW recipient or > 2 x 108 nucleated cells/kg BW recipient or· Karnofsky Index > 80 % · Age > 0 and < 70 years· Adequate contraception in female patients of child-bearing potential · Written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Secondary malignancies2. A hematopoietic cell transplantation-specific comorbidity index (Sorror et al Appendix B) > 43. Known and manifested malignant involvement of the CNS 4. Active infectious disease 5. Active HIV, HBV or HCV infection6. Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper normal limit)7. Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x upper normal limit).8. Pleural effusion or ascites > 1.0 L 9. Pregnancy or lactation10. Known hypersensitivity to treosulfan and/or fludarabine and/or rapamycin11. Participation in another experimental drug trial within 4 weeks before day -612. Non-co-operative behaviour or non-compliance 13. Psychiatric diseases or conditions that might impair the ability to give informed consent
研究者
相似试验
已完成
1 期
Development of treosulfan-based conditioning regimen for congenital metabolic diseases; Phase I studyMucopolysaccharidosis type I (Herler syndrome), type II (Hunter syndrome)JPRN-UMIN000009758Tokai University School of Medicine12
进行中（未招募）
1 期
Clinical study in which are enrolled patients with malignant hematologic diseases for which there is no indication for allogeneic bone marrow transplantation, and for whom a suitable donor has been identified (fully compatible or partially compatible).EUCTR2011-001534-42-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR67
Unknown
2 期
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological MalignanciesHematological MalignanciesAllogeneic TransplantationNCT00129155Hospices Civils de Lyon30
终止
2 期
Stem Cell Transplantation for Hematological MalignanciesLeukemia, Lymphocytic, AcuteMDSAMLNCT00176839Masonic Cancer Center, University of Minnesota11
已完成
3 期
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)Acute Myeloid LeukemiaMyelodysplastic SyndromeNCT00822393medac GmbH570